March 15 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix announces receipt of notice of allowance from the united states patent and trademark office
* Resverlogix -receipt of notice of allowance from uspto for patent claims covering use of apabetalone in combination with rosuvastatin in united states
* Resverlogix corp says rosuvastatin was exclusively marketed by astrazeneca under trade name crestor until its patent expired in 2016 Source text for Eikon: ID:nCNWmlFXYa Further company coverage: RVX.TO